



# Newsletter articles about drugs covered under the medical benefit

For Blue Care Network commercial

Revised November 2020

This document contains links to newsletter articles about drugs covered under the medical benefit.

## ***The Record, November 2020***

- [Prior authorization lists for medical specialty drugs will change in November for some members](#)
- [Quarterly update: Requirements changed for some commercial medical benefit drugs](#)
- [Blue Cross and BCN further extend authorization end dates on select medical and pharmacy benefit drugs for Medicare Advantage members](#)

## ***BCN Provider News, November-December 2020***

- Page 34: [We'll change how we cover some drugs, starting Jan. 1](#)
- Page 40: [Medical specialty drug prior authorization lists will change in November for certain members](#)

## ***The Record, September 2020***

- [Medical specialty drug prior authorization lists changing for Medicare Plus Blue, BCN commercial and BCN Advantage](#)

## ***BCN Provider News, September-October 2020***

- Page 24: [Effective Oct. 1, Nivestym and Zarxio are the preferred filgrastim products for all Blue Cross and BCN commercial and Medicare Advantage members](#)
- Page 25: [Medical specialty drug prior authorization lists are changing in September for BCN HMO, Medicare Plus Blue PPO and BCN Advantage members](#)
- Page 26: [Quarterly update: Requirements changed for some medical benefit drugs for BCN HMO members](#)
- Page 27: [Blue Cross and BCN will have preferred hereditary angioedema medications for our commercial members, effective Nov. 1](#)

## ***The Record, August 2020***

- [Effective Oct. 1, Nivestym and Zarxio are preferred filgrastim products](#)

## ***The Record, July 2020***

- [Starting July 1, 2020, Praluent and Repatha will no longer be designated as specialty drugs](#)
- [Quarterly update: Requirements changed for some commercial medical benefit drugs](#)



# Newsletter articles about drugs covered under the medical benefit

For Blue Care Network commercial

Revised November 2020

## ***BCN Provider News, July-August 2020***

- Page 27: [Recommendations for submitting authorization requests for medical oncology drugs to AIM](#)
- Page 28: [Medical benefit specialty drug prior authorization lists are changing in July and August for Medicare Plus Blue PPO, BCN HMO and BCN Advantage members](#)
- Page 29: [We've added a document online with program information for site-of-care requirements for Lemtrada and Tysabri](#)

## ***The Record, May 2020***

- [Quarterly update: Requirements changed for some commercial medical benefit drugs](#)

## ***BCN Provider News, May-June 2020***

- Page 17: [We're adding site of care requirements for Lemtrada and Tysabri for commercial members](#)
- Page 18: [Quarterly update: Requirements changed for some commercial medical benefit drugs](#)

## ***The Record, March 2020***

- [We're adding site-of-care requirements for Lemtrada and Tysabri for commercial members, starting May 1](#)
- [Update: Requirements changed for some commercial medical benefit drugs](#)
- [Two medical drugs going on commercial site-of-care program, starting April 1](#)

## ***BCN Provider News, March-April 2020***

- Page 28: [We've changed requirements for some commercial medical benefit drugs](#)
- Page 29: [We're adding two medical drugs to the site of care program for Blue Cross and Blue Care Network commercial members starting April 1](#)

## ***BCN Provider News, January-February 2020***

- Page 35: [Blue Care Network will no longer cover select drugs under the medical benefit for commercial members starting in February](#)
- Page 36: [We'll cover select hyaluronic acid products, starting Jan. 1](#)

## ***The Record, December 2019***

- [J0642 replaces J3490 and J3590 when billing levoleucovorin \(khapsory\)](#)



# Newsletter articles about drugs covered under the medical benefit

For Blue Care Network commercial

Revised November 2020

## ***The Record, November 2019***

- [Blue Cross and BCN to cover select hyaluronic acid products, starting Jan.1](#)

## ***BCN Provider News, November-December 2019***

- Page 25: [We'll cover hemophilia drugs under the pharmacy benefit for most commercial HMO and PPO members, starting Jan. 1](#)

## ***The Record, September 2019***

- [Quarterly update: Requirements changed for some commercial medical benefit drugs](#)

## ***BCN Provider News, September-October 2019***

- Page 27: [Additional medical benefit specialty drugs have authorization and site-of-care requirements for BCN HMO members, effective Oct 1](#)
- Page 28: [Quarterly update: Medical drug authorization and site-of-care requirements for BCN HMO and Blue Cross' PPO members](#)
- Page 30: [2019 IVIG dosing strategy is changing, starting Oct. 1](#)

## ***The Record, August 2019***

- [Immune, subcutaneous globulin dosing strategy changing](#)

## ***BCN Provider News, July-August 2019***

- Page 26: [BCN oncology management program begins August 1](#)

## ***BCN Provider News, May-June 2019***

- Page 25: [Inflectra to be the preferred infliximab product for adult BCN Commercial members](#)

## ***BCN Provider News, March-April 2019***

- Page 24: [Fasenra and Radicava are subject to a site-of-care requirement for BCN HMO members, effective April 1](#)

## ***BCN Provider News, January-February 2019***

- Page 25: [We've added drugs to the medical benefit specialty drug prior authorization program](#)
- Page 33: [Medical Drug Prior Authorization and Site of Care programs expanded](#)